May 14, 2025 08:05AM IN8bio, Inc (INAB) Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

Mar 17, 2025 06:41AM IN8bio Inc. (INAB) PT Lowered to $6 at H.C. Wainwright

Mar 13, 2025 04:16PM IN8bio, Inc. (INAB) Misses Q4 EPS by 1c

Mar 3, 2025 09:32AM IN8bio, Inc (INAB) unveils INB-600 Gamma-Delta TCE platform

Feb 14, 2025 09:00AM IN8bio, Inc (INAB) Presents Positive Phase 1 Data at TCT 2025

Feb 11, 2025 10:50AM Jones Trading Upgrades IN8bio Inc. (INAB) to Buy

Feb 11, 2025 08:00AM IN8bio, Inc (INAB) Reports Updated Positive Results from Phase 1 Trial of INB-100

Dec 10, 2024 07:04AM IN8bio, Inc (INAB) Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias

Nov 26, 2024 07:05AM H.C. Wainwright Reiterates Buy Rating on IN8bio Inc. (INAB)

Nov 25, 2024 07:01AM IN8bio, Inc (INAB) Reports Continued Durable Remissions in Phase 1 Trial of INB-200

Nov 14, 2024 07:50AM IN8bio Inc. (INAB) PT Lowered to $2 at Mizuho

Nov 13, 2024 06:56AM IN8bio Inc. (INAB) PT Lowered to $8 at H.C. Wainwright

Nov 12, 2024 04:31PM IN8bio, Inc. (INAB) Tops Q3 EPS by 2c

Oct 1, 2024 08:01AM IN8bio, Inc (INAB) Prices $12.4M Offering at $0.395/unit

Sep 4, 2024 04:02PM IN8bio, Inc (INAB) Announces Clinical Pipeline Prioritization to Focus on INB-100, Cuts 49% Staff

Aug 12, 2024 08:06AM IN8bio, Inc (INAB) reports positive clinical data from Phase 1 trials of INB-100 for hematological malignancies and INB-200 for GBM

Aug 9, 2024 07:40AM IN8bio, Inc. (INAB) Misses Q2 EPS by 2c

Jun 14, 2024 02:30PM Laidlaw Reiterates Buy Rating on IN8bio Inc. (INAB)

Jun 14, 2024 06:00AM IN8bio Inc. (INAB) PT Raised to $6.50 at Jones Trading

Jun 13, 2024 04:01PM IN8bio, Inc (INAB) Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100